Med BioGene Inc.

GeneFx Lung is a proprietary gene expression-based test to improve upon staging for identifying those patients with early-stage non-small-cell lung cancer (NSCLC) who, following surgical removal of their tumor, are at higher and lower risks of mortality.

Precision, a leading life science company based in Pittsburgh, Pennsylvania, is dedicated to improving the outcomes of cancer patients by providing personalized medicine solutions that aim to increase quality of life and cancer survival rates. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the continuum of cancer care.

Med BioGene Inc. (MBI: TSX Venture) is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests.

Med BioGene Inc. (MBI) is a life science company based in Vancouver, British Columbia, that is currently focused on managing the license and rights to GeneFx® Lung (formerly, LungExpress Dx), a proprietary gene expression-based test for early-stage non-small-cell lung cancer. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. MBI has partnered with Precision Therapeutics for the global commercialization of GeneFx Lung. MBI's common shares are traded on the TSX Venture Exchange.